AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Other Events
Item 8.01
On September 23, 2019, Avadel Pharmaceuticals plc issued a press release, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
(d) Exhibits
| 99.1 | Press release dated September 23, 2019, issued by Avadel Pharmaceuticals plc |
AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tv529876_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019 ·FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate,…
To view the full exhibit click here